Immune checkpoint inhibition transformed human oncology over the past decade — and veterinary medicine is now following the same path. The U.S. Department of Agriculture has conditionally licensed the first anti-PD-1 antibody for treating canine mast cell tumors and melanoma, establishing checkpoint blockade as a clinically validated strategy in companion animals, not just a research curiosity. For comparative oncology researchers, this creates a growing need for well-characterized canine-reactive checkpoint reagents that can support both spontaneous tumor models in dogs and cross-species mechanism studies relevant to human immuno-oncology.
This guide introduces abinScience's newly added Anti-Canine PD-L1 antibody and places it within the broader canine immune checkpoint toolkit available for veterinary and comparative oncology research.
Why Canine PD-L1 Matters for Comparative Oncology
Dogs develop spontaneous tumors — melanoma, osteosarcoma, mammary carcinoma, and others — that share meaningful biological and clinical similarities with their human counterparts, including intact immune systems and naturally occurring tumor heterogeneity that mouse xenograft models often lack. This makes canine cancer a valuable comparative model for evaluating checkpoint-targeted therapies before or alongside human clinical development.
PD-L1 (CD274/B7-H1) is expressed on tumor cells and tumor-infiltrating immune cells across multiple canine cancer types, where it engages PD-1 on T cells to suppress anti-tumor immune responses—mirroring the human PD-1/PD-L1 axis targeted by checkpoint inhibitors like pembrolizumab and nivolumab. Reliable canine-reactive PD-L1 antibodies are essential for characterizing checkpoint expression in tumor biopsies, validating in vitro blocking assays, and supporting biomarker studies alongside veterinary clinical trials.
New: Anti-Canine PD-L1/B7-H1 Recombinant Antibody (12C10E4)
abinScience has added a recombinant monoclonal antibody targeting canine PD-L1/B7-H1, clone 12C10E4, to its comparative oncology catalog. As a recombinant antibody, it offers defined sequence identity and improved lot-to-lot consistency compared to traditional hybridoma-derived clones — an important consideration for researchers running longitudinal studies across multiple tumor cohorts.
Paired with the existing Canine CD274/PD-L1/B7-H1 Recombinant Protein (CV974011), researchers can validate antibody binding and set up ELISA or blocking assays without waiting on primary tumor tissue.
The Broader Canine Immune Checkpoint Toolkit
PD-L1 is one node in a larger checkpoint and immune-marker network relevant to veterinary immuno-oncology. abinScience's canine reagent catalog—spanning 220 canine-reactive products—includes reference antibodies, recombinant proteins, and flow-validated antibodies across the major checkpoint targets:
| Catalog No. |
Product |
Target |
Research Relevance |
| CV974013 |
Anti-Canine PD-L1/B7-H1 Recombinant Antibody (12C10E4) |
PD-L1/CD274 |
Checkpoint expression profiling; newly added |
| CV974011 |
Canine CD274/PD-L1/B7-H1 Recombinant Protein (C-His) |
PD-L1/CD274 |
ELISA standard, antibody validation, blocking assay development |
| CS870016 |
Anti-Canine PD-1 Reference Antibody (Gilvetmab, RUO) |
PD-1 |
RUO reference standard for the first USDA-conditionally-licensed canine checkpoint inhibitor |
| CS870011 |
Canine PD-1 Recombinant Protein (C-His) |
PD-1 |
Receptor-side standard for PD-1/PD-L1 axis studies |
| CB651016 |
Anti-Canine CTLA-4 Reference Antibody (12B3, RUO) |
CTLA-4/CD152 |
Complementary checkpoint target for combination blockade research |
| CB613011 |
Canine CD223/LAG3 Recombinant Protein (C-Fc) |
LAG-3 |
Emerging checkpoint target for T-cell exhaustion studies |
| CV029011 |
Canine CD366/HAVCR2/TIM-3 Recombinant Protein (C-Fc) |
TIM-3 |
Additional exhaustion marker for multi-checkpoint panels |
| CY286011 |
Canine CD340/ERBB2/HER2/NEU Recombinant Protein (C-His) |
HER2/ERBB2 |
Comparative model for HER2+ mammary tumors alongside checkpoint studies |
Notably, the Gilvetmab reference antibody corresponds to the active ingredient in the first USDA-conditionally licensed anti-PD-1 therapy for canine mast cell tumors and melanoma—giving researchers an RUO tool to benchmark new candidate antibodies against a clinically established comparator. For the full set of 220 canine-reactive research reagents, browse the canine research reagent catalog →
Getting Started with Canine Checkpoint Research
For expression profiling in tumor biopsies: Pair the Anti-Canine PD-L1 antibody (12C10E4) with IHC or flow cytometry workflows to characterize checkpoint expression across tumor types and correlate with clinical outcomes.
For in vitro blocking/functional assays: Use the recombinant PD-L1 and PD-1 proteins together to establish a binding or blocking baseline before testing candidate antibodies or combination approaches.
For benchmarking against approved therapy: The Gilvetmab reference antibody provides a defined comparator for evaluating novel anti-PD-1 candidates against the current clinical standard in veterinary oncology.
Building a Canine Immuno-Oncology Panel?
abinScience offers 220 canine-reactive research reagents spanning PD-L1, PD-1, CTLA-4, LAG-3, TIM-3, HER2, and more — supporting both veterinary clinical research and comparative immuno-oncology studies. Browse the full canine catalog → or contact our technical team at support@abinscience.com for target-specific recommendations.
中文
English
한국어
日本語
Español
Français
Русский
